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Early institution of effective antibiotic therapy and source control are pivotal to improve sur-
vival of abdominal septic patients. Xpert1 Carba-R is a real time polymerase chain reaction
assay for rapid detection and differentiation of five genes (blaKPC, blaVIM, blaOXA-48, blaIMP-1,
blaNDM) responsible for carbapenem resistance. We performed an observational study
investigating the clinical usefulness and applicability of Xpert1 Carba-R to detect carbape-
nem resistance in abdominal septic patients admitted to intensive care unit. We compared
the results of Xpert1 Carba-R with standard microbiological culture. We collected a set of
two rectal/stomia swabs and two swabs from abdominal drainage fluid for each patient. We
included 20 patients for a total of 45 comparisons between the two methods. In our clinical
setting, the overall performance of Xpert1 Carba-R for detection of carbapenem resistance
in the presence of genes detectable and non-detectable by the method was: sensitivity 50%
(95% CI 24.6–75.3); specificity 93.1% (95% CI 77.2–99.1); positive predictive value (PPV)
80% (95% CI 44.4–97.5); negative predictive value (NPV) 77.1% (95% CI 56.9–89.6). The
inter-rater agreement was 0.47 (SE 0.14; 95% CI 0.20–0.74). When considering the only 5
mechanisms of resistance detected by both methods, the overall diagnostic performance
was: sensitivity 100% (95% CI 69.1–100), specificity 94.2 (95% CI 80.8–99.3), PPV 83.3
(95% CI 59.6–97.9) and NPV 100% (95% CI 89.4–100). The inter-rater agreement was
0.88 (SE 0.08; 95% CI 0.71–1). Xpert1 Carba-R may be considered an additional diagnos-
tic tool for early diagnosis of carbapenem resistance in abdominal septic patients. Clinicians
should be aware of their epidemiology before its introduction in the diagnostic protocol of
their intensive care units.
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Introduction
Infections caused by microorganisms with resistance to carbapenems are associated with a high
morbidity and mortality. These microorganisms are frequently responsible for intra-abdominal
infections due to the increasing patients’ colonization by multidrug resistant organisms
(MDROs). [1–4] Effective antibiotic treatment is a mainstay of management of sepsis of intra-
abdominal origin, in association with early resuscitation and source control. [5–8] Carbapenem
resistance makes empirical and targeted treatment of abdominal infections challenging, due to
the high risk of ineffectiveness of commonly used antibiotics (e.g. cephalosporins, carbapenem)
and the need to adopt alternative antibiotic strategies (e.g. combination regimens). [4, 9] Early
detection of antibiotic resistance may be useful for rapid institution of effective antibiotic treat-
ment and for improving patients’ outcome. [7] Conversely, turnaround time needed for culture-
based detection of carbapenem resistance is relatively long. [10] Non culture-based methods may
reduce the time needed to get the antibiotic resistance data leading to an earlier institution of an
effective antimicrobial treatment. [11] For this purpose, polymerase chain reaction (PCR) assays
are the most widely used and studied methods. However, their diagnostic performance, agree-
ment with culture-based techniques and clinical usefulness is not definitely established. [11, 12]
Xpert1 Carba-R is a real time PCR assay for rapid detection and differentiation of five
genes (blaKPC, blaVIM, blaOXA-48, blaIMP-1, blaNDM) associated with non-susceptibility to carba-
penem in Gram-negative bacteria, mostly belonging to the Enterobacteriaceae family. [1] The
reports of its clinical application have been rare and mostly related to the identification of colo-
nization for surveillance and screening purposes. [13, 14] Our aim was to test applicability and
reliability of Xpert1 Carba-R in a clinical setting characterised by a relatively high prevalence
of colonization and infections by carbapenem resistant bacteria. We evaluated the clinical use-
fulness of Xpert1 Carba-R for rapid detection of carbapenem resistant bacteria compared to
microbiological culture in critically ill patients with abdominal sepsis.
Methods
Study design
We performed a single-centre observational prospective study from September 2014 to December
2015 in the General Intensive Care Unit in cooperation with the Hygiene Section, Department of
Science for Health Promotion and Mother-Child Care of the University hospital Policlinico “P.
Giaccone”, Palermo, Italy. The Ethics Review Board (Comitato Etico Palermo 1) approved the
study protocol and we obtained written informed consent from every included patient or their rel-
atives. The enrolled patients met the following inclusion criteria: 1) severe sepsis or septic shock at
the moment of ICU admission or at any time during ICU stay basing on international sepsis crite-
ria [15] by attending physicians; 2) admission to ICU related to either elective or emergent
abdominal surgery; 3) proven or suspected intra-abdominal infection as primary focus of septic
state. Exclusion criteria were: 1) no informed consent; 2) abdominal surgery not involving the
digestive tract, including pancreas and biliary tract; 3) samples for one of the tests obtained more
than 30-minutes apart; 4) inability to perform the complete sequence of actions from sampling to
processing of the specimens set within 12 hours; 5) readmission within 5 days from the ICU dis-
charge. For every consecutive patient matching the inclusion criteria we obtained a set of two
swabs from both rectum or stomia (if any) faecal material and two swabs from fluid of abdominal
drainages most close to the site of abdominal surgery. For the purpose of the study, we used the
term stomia to indicate any surgical opening of the gastrointestinal tract to the abdominal wall.
One swab from rectum/stomia and one swab from abdominal drainage fluid was sent to the
laboratory and processed for standard microbiological cultures. Another swab from rectum/
Cepheid Xpert Carba-R1 in Abdominal Septic Patients
PLOS ONE | DOI:10.1371/journal.pone.0160643 August 4, 2016 2 / 10
stomia and another from abdominal drainage fluid were tested by Xpert1 Carba-R. We per-
formed blood cultures at admission in all included patients according to our institutional pro-
tocol. Nurses were in charge for the first part of our ICU protocol aimed to obtain samples
from rectum/stomia faecal material and fluid from abdominal drainages for microbiological
culture and Xpert1 Carba-R.
We registered demographic and clinical data about the enrolled patients including patient ori-
gin (e.g. emergency department, surgical ward, operating room), information about abdominal
surgery (type, site, urgency, whether first or re-intervention), previous antibiotic regimen, Sequen-
tial Organ Failure Assessment score (SOFA) at the time of study inclusion. We also collected the
results of microbiological cultures, identified microrganisms, Minimum Inhibitory Concentration
(MIC) of imipenem and meropenem, genetic determinants of carbapenem resistance and turn-
around time to obtain results of antibiogram.We further recorded results from Xpert1 Carba-R
in terms of detection of resistance-associated genes, and turn-around time to the result.
Microbiological cultures and Xpert1 Carba-R tests
Culture-based methods. For cultural screening each swab, after an overnight incubation
in Brain Heart Infusion broth (Oxoid, Basingstoke Hampshire, United Kingdom), was inocu-
lated onto a MacConkey agar plate (Oxoid, Basingstoke Hampshire, United Kingdom) with a
10μg meropenem disk (Oxoid, Basingstoke Hampshire, United Kingdom). MacConkey agar
plates were incubated at 35°C overnight. All the morphologically different colonies growing
into the meropenem disk halo were picked up and subcultured for purity. The bacterial identi-
fication was performed by biochemical standard assays. MIC values of meropenem and imipe-
nem were assessed by E-test strips (BioMerieux, Marcy-l’Etoile, France). The isolates were
identified as resistant to carbapenems according to the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) breakpoints. [16, 17] We adopted updated EUCAST break-
points tables (version 4.0 for 2014 and then 5.0 for 2015).
PCR-based methods. Molecular analysis was carried out on the swabs using the Cepheid
Xpert1 Carba-R assay and the GeneXpert1 device (Cepheid, Sunnyvale, USA). This test,
based on an automated real-time
PCR, is designed for rapid detection and differentiation of the blaKPC, blaNDM, blaVIM,
blaOXA-48, and blaIMP-1 gene sequences associated with carbapenem-non-susceptibility in
Gram-negative bacteria, mostly belonging to the Enterobacteriaceae family. All swabs from
both rectum/stomia and abdominal drainage fluid were processed according to the same proce-
dure. More in details, each swab was placed into a vial of the sample reagent (Cepheid, Sunny-
vale, USA) and vortexed at high speed for 10 seconds. Then, 1.7 ml of the suspension was
transferred into the sample chamber of the Xpert1 Carba-R cartridge. The results were inter-
preted by the GeneXpert System from measured fluorescent signals and shown on the View
Results window. When carbapenem resistance was detected by microbiological culture, we per-
formed specific in-house PCR for the blaKPC, blaNDM, blaVIM, blaOXA-48, and blaIMP-1 [18–21].
Further molecular tests were performed with specific in-house PCR for additional carbape-
nem resistance genes, namely blaOXA-23, blaGES, blaPER and blaVEB, frequently encountered in
our setting [18–21], when 1) Xpert1 Carba-R resulted negative but microbiological culture
showed carbapenem resistance 2) when there was evidence of polymicrobial growth from
microbiological culture.
Statistical analysis
We analysed variables distribution by the D’Agostino-Pearson test. We calculated and reported
mean and standard deviation for variables with normal distribution. We expressed variables
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without normal distribution with median and interquartile range (25th-75th). We compared
variables with normal distribution using the Student’s t test. Mann-Whitney test was used for
variables with non normal distribution. We calculated inter-rater agreement using the non-
weighted Cohen’s k along with standard error (SE) and 95% confidence interval (95% CI). We
interpreted Cohen’s k values according to Altman et al. We considered concordance either the
detection of carbapenem resistance by both culture and Xpert Carba-R or the negative results
by both methods. We calculated sensitivity, specificity, positive predictive value (PPV) and
negative predictive value (NPV) of detecting a carbapenem resistance by Xpert1 Carba R
when compared to microbiological culture. Our cohort represented a convenience sample of
patients with the pre-specified inclusion criteria. We considered a p-value< 0.05 as statistically
significant. We used MedCalc1 for Windows version 9.5.0.0 (MedCalc Software, Mariakerke,
Belgium) for statistical analysis.
Results
We screened for inclusion a total amount of 49 patients. Eight patients were excluded for lack
of informed consent, 16 for the inability to perform the complete sequence of actions (from
sampling to processing of the set of specimens) within the pre-specified cut-off time and 5
were excluded because of readmission within 5 days. We included 20 patients in the study.
Three patients were included twice in the study since they were readmitted to the ICU after 5
days due to abdominal post surgical complications. We collected a total of 22 complete sets of
specimens and one incomplete set since one patient did not have abdominal post-surgical
drainage. Characteristics of included patients are summarized in Table 1. Of 23 sets of
Table 1. Demographic and clinical characteristics of patients included in the study.





Functional status Autonomous: 12/23
Not-autonomous 11/23
Patient origin Surgical ward: 15/23 Operating room: 6/23
Medical ward: 2/23
Days between hospital and ICU admission
(mean, SD)
10.1 (8.67)




SOFA at the enrolment in the study (median,
IQR)
(9.0, 7.25–12.0)
Type of surgery Urgent: 22/23
Elective: 1/23
Site of surgery Colon (7/23; 30.4%) Colorectal (7/23; 30.4%) Small intestine
(6/23; 26.1%)
Pancreas (1/23; 4.35% Biliary tract (1/23; 4.35%) Stomach
(1/23; 4.35%)
Reintervention 15/23 (65.2%)
F: female; IQR: interquartile range; M: male; SD: standard deviation. (Total number of included patients: 20.
Total number of ICU admissions: 23).
doi:10.1371/journal.pone.0160643.t001
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specimens from either rectum or stomia, 12 were obtained from rectum and 11 from post-sur-
gical stomia. The overall number of comparison between the two methods regardless of the
sampling site was 45 (22 complete comparisons + 1 comparison from stomia only). Mean turn-
around time for results by Xpert1 Carba-R was 88.2 minutes (SD: 8.56) compared to approxi-
mately to 72 hours needed for identification of carbapenem resistant strains by culture. Nine
out of 23 (39.1%) specimens from rectum/stomia resulted positive for carbapenem resistant
bacteria whereas 14 (60.9%) resulted negative by microbiological cultures. Five out of 23
(21.7%) specimens from rectum/stomia resulted positive and 18 (78.3%) resulted negative for
Xpert1 Carba-R. Concerning specimens from rectum/stomia, 4 resulted positive and 13
resulted negative for both cultural and molecular assays. Five specimens resulted positive for
microbiological culture and negative for Xpert1 Carba-R. One specimen resulted negative for
microbiological cultures and positive for Xpert1 Carba-R. Microbiologial cultures from rec-
tum/stomia specimens isolated the following microorganisms: A. baumannii (5 isolations), K.
pneumoniae (4 isolations), P. aeruginosa (3 isolations), Enterobacter spp (1 isolation), E. coli (1
isolation). Among isolates from rectum/stomia, we detected the following mechanisms of car-
bapenem resistance: 5 OXA-23, 4 KPC, 1 VIM. For one carbapenem resistant isolate, it was not
possible to identify the mechanism of resistance since it was not among the tested ones.
Xpert1 Carba-R detected 4 KPC, 1 VIM, 1 OXA-48. Seven out of 22 (21.8%) specimens from
abdominal drainages resulted positive whereas 15 (78.2%) resulted negative for microbiological
culture. Five abdominal drainage specimens resulted positive (21.7%) and 17 (78.3%) resulted
negative for Xpert1 Carba-R. Four specimens resulted positive and fourteen resulted negative
for both cultural and molecular assays. Three specimens resulted positive for microbiological
culture and negative for Xpert1 Carba-R. One specimen resulted negative for microbiological
culture and positive for Xpert1 Carba-R. Microbiological cultures from drainages specimens
isolated the following microorganisms: A. baumannii (4 isolations), K. pneumoniae (4 isola-
tions), P. aeruginosa (2 isolations), Candida albicans (1 isolation). Isolates from abdominal
drainages carried the following mechanisms of resistance: 4 KPC, 2 OXA-23, 1 VIM, 1 OXA-
48, 1 GES, 1 PER. Xpert1 Carba-R identified 4 KPC, 1 VIM, 1 OXA-48. Specimens, which
tested positive by at least one method, are described in Table 2. In 9 out of 10 sets, which tested
positive for carbapenem resistant bacteria in rectum/stomia specimens, a positive blood culture
was also reported. When we considered positive results from drainage, in 7 out of 9 positive
samples, a positive blood culture was also observed. In 5 out of 9 sets with at least one positive
result by Xpert1 Carba-R, we observed also a positive blood culture result. Table 3 describes
the inter-rater agreement of Xpert1 Carba-R compared to cultures from rectum/stomia and
drainage specimens, along with the performance of Xpert1 Carba-R when we considered all
genes of carbapebems resistance (both detectable and non detectable by Xpert1 Carba-R). The
overall inter-rater agreement (Cohen’s K) for detection of carbapenem resistance for both
assays was 0.47 (SE 0.14; 95% CI 0.20–0.74). The overall performance of Xpert1 Carba-R for
detection of carbapenem resistance was as follows: sensitivity 50% (95% CI 24.6–75.3); specific-
ity 93.1% (95% CI 77.2–99.1); PPV 80% (95% CI 44.4–97.5); NPV 77.1% (95% 56.9–89.6).
When considering the only 5 mechanisms of resistance (KPC, VIM, OXA-48, IMP-1, NDM)
detected by both methods, the overall inter-rater agreement (Cohen’s K) for detection of carba-
penem resistance was 0.88 (SE 0.08; 95% CI 0.71–1). The overall diagnostic performance was
as follows: sensitivity was 100% (95% CI 69.1–100), specificity 94.2 (95% CI 80.8–99.3), PPV
83.3 (95% CI 59.6–97.9) and NPV 100% (95% CI 89.4–100). Table 4 summarizes the inter-
rater agreement with microbiological culture and the performance of Xpert1 Carba-R when
considering only the 5 mechanisms of resistance (KPC, VIM, OXA-48, IMP-1, NDM) detected
by both methods.
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Discussion
To our knowledge, this is the first study specifically testing the clinical diagnostic usefulness of
Xpert1 Carba-R assay in a cohort of septic abdominal patients.
In all specimens resistant to carbapenems by phenotypical method (E-test) and possessing
genes detectable by Xpert1 Carba-R, there was a concordance between the two methods.
In some cases, we registered carbapenem resistance to culture-based method along with
negative Xpert1 Carba-R. In 6 of these cases, in-house PCR detected OXA-23 and, in other 2
cases, GES and PER. In another case, the gene responsible for carbapenem resistance was not
identified since all in-house PCR resulted negative. According to our results, we may argue that
the inclusion of additional carbapenem resistance genes in the molecular tests (e.g. OXA-23)
would improve the diagnostic performance and clinical usefulness of this technique. In two
patients samples, Xpert1 Carba-R identified blaOXA-48 as responsible mechanism of carbape-
nem resistance. In these 2 samples, a late and weak positive signal was observed and no carba-
penem resistant strain was isolated on McConkey Agar plate. We supposed that these two
Table 2. Descripition of positive specimens from at least one site by either microbiological cultures or Xpert Carba-R. Genetic determinants (GDs)
of carbapenem resistance were detected by in-house PCR.
Rectum/stomia culture GDs Rectum/stomia Xpert
Carba-R
Drainage culture GDs Drainage Xpert
Carba-R
Blood culture
P. aeruginosa GES+ PER+ Negative Negative / Negative P. aeruginosa









KPC VIM K. pneumonia A.
baumanniiVIM
A. baumanniiA. baumannii
K. pneumoniae KPC KPC K. pneumoniae KPC KPC K. pneumoniae
A. baumannii OXA-23 Negative A. baumannii OXA-23 Negative A. baumannii
Negative / Negative P. aeruginosa GES+PER+ Negative Negative
K. pneumoniae KPC KPC K. pneumoniae KPC KPC K. pneumoniae
A. baumanniii OXA-23 Negative A. baumannii OXA-23 Negative A. baumannii
P. aeruginosa Not detected Negative Negative / Negative Negative
A. baumannii OXA-23 Negative Negative / Negative A. baumanii
K. pneumoniae KPC KPC K. pneumoniae KPC KPC K. pneumoniae
Negative / OXA-48 Not available / Not available Negative
A. baumannii K.
pneumoniae




Negative / Negative Negative / OXA-48 Negative
GDs = genetic determinants of carbapenem resistance
doi:10.1371/journal.pone.0160643.t002
Table 3. Performance of Xpert Carba-R in comparison with microbiological culture for detection of carbapenem resistance by all genes (detect-
able and non detectable by bothmethods) in our cohort of patients.
Rectum/stomia specimen Drainage specimen Overall
Inter-rater agreement (Cohen’s K) 0.41 (SE 0.19; 95% CI 0.04–0.77) 0.44 (SE 0.19; 95% CI 0.08–0.82) 0.47 (SE 0.14; 95% CI 0.20–0.74)
Sensitivity 44.4% (95% CI 13.7–78.8) 57.1% (95% CI 18.4–90.1%) 50% (95% CI 24.6–75.3)
Speciﬁcity 92.9% (95% CI 66.1–99.8); 93.3% (95% CI 68.1–99.8) 93.1% (95% CI 77.2–99.1)
PPV 80% (95% CI 28.4%–99.5%); 80% (95% CI 28.4–99.5%) 80% (95% CI 44.4–97.5)
NPV 72.2% (95% CI 46.5–90.3) 82.4% (95% 56.6–96.2) 77.1% (95% 56.9–89.6)
PPV = positive predictive value; NPV = negative predictive value
doi:10.1371/journal.pone.0160643.t003
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results were possibly related to non-vital bacteria or residual DNA or that the amount of bacte-
rial cells in the clinical specimen was below the detection limit of the culture-based method.
This discrepancy in isolation is common among PCR techniques applied to microbiological
diagnosis, leading to unclear clinical significance. [11] Discrepancies between molecular and
standard methods are well known for OXA-48 gene family because of its low enzymatic activity
against carbapenems yielding MICs lower than the resistance cut-off value. Nevertheless,
OXA-48-like-producing bacteria are typically resistant to carbapenems, as a consequence of
concurrent resistance mechanisms, such as porin defects or production of other β-lactamases.
[22] In our study, mean turnaround time for results by Xpert1 Carba-R was less than one hour
and half, compared to about 3 days required by culture-based method. Although this difference
may be an advantage in terms of timing of effective antibiotic therapy institution, clinicians
should be aware of the limitations of the technique.
To date, Xpert1 Carba-R diagnostic performance has been studied in comparison with
standard blood cultures and other PCR techniques. A recent report from Saudi Arabia
described the failure of Xpert1 Carba-R to detect multiple coexisting resistance mechanisms.
[23] Conversely, in one of our cases, Xpert1 Carba-R was able to detect two coexisting mecha-
nisms of resistance (KPC and VIM). A report from Korea studied the performance of Xpert1
Carba-R, in comparison with standard culture methods, in an unselected ICU cohort of
patients to determine intestinal colonization rates of carbapenemase-producing organisms.
Clinical samples included stool samples and rectal swabs. Of note, duplicates samples from the
same patients were excluded. Moreover, authors did not calculate an overall measure of con-
cordance between standard cultures and Xpert1 Carba-R. [14] More recently, reports of inabil-
ity to detect OXA-48-like genes have been published. OXA-181 is an allele of the OXA-48
family. More than 120 alleles of the so-called big 5 genes of carbapenem resistance genes have
been identified, leading to a potential reduced sensitivity of the RT-PCR assay. Notably, OXA-
48 was subsequently added to the original 4-gene detection kit of Xpert1 Carba-R in order to
cover the big five genes most frequently responsible for carbapenem resistance according to
different epidemiologic reports. [24] Due to the emergence and spread of different genes of
resistance other than the big five (e.g. OXA-23) and alleles within each family of genes of carba-
penem resistance (e.g. OXA-181), [25] Xpert1 Carba-R and other RT-PCR based techniques
should be considered a dynamic compromise for detection of currently most influent genes.
This study has some limitations. Firstly, our convenience sample size was relatively small
due to our limited available resources for this study. However, to our knowledge, it was the first
attempt to study the performance of the Xpert1 Carba-R assay in this setting before a more
extended use. Another limitation may be attributed to the limited number of genes detected by
the Xpert1 Carba-R. According to a review of our microbiological reports of the last 3 years,
blaKPC, blaNDM, blaVIM, blaOXA-48, and blaIMP-1 accounted for the majority of genes responsible
for carbapenem resistance in our ICU. However, this could not prevent the emergence of other
Table 4. Performance of Xpert Carba-R assay in comparison with microbiological culture for detection of carbapenem resistance when consider-
ing only the 5 mechanisms of resistance (KPC, VIM, OXA-48, IMP-1, NDM) detected by both methods.
Rectum/stomia specimen Drainage specimen Overall
Inter-rater agreement (Cohen’s K) 0.88 (SE 0.11, 95% CI 0.65–1) 0.87 (SE 0.11, 95% CI 0.64–1) 0.88 (SE 0.08, 95% CI 0.71–1)
Sensitivity 100% (95% CI 47.8–100) 100% (95% CI 47.8–100%) 100% (95% CI 69.1–100)
Speciﬁcity 94.4 (95% CI 72.7–99.8) 94.1 (95% CI 71.3–99.8) 94.2 (95% CI 80.8–99.3)
PPV 83.3 (95% CI 35.8–99.5) 83.3 (95% CI 35.8–99.6) 83.3 (95% CI 59.6–97.9)
NPV 100% (95% CI 80.5–100) 100 (95% CI 79.4–100) 100% (95% CI 89.4–100)
SE = standard error, PPV = positive predictive value; NPV = negative predictive value
doi:10.1371/journal.pone.0160643.t004
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carbapenem resistance mechanisms during the study period. Indeed, in 3 cases we detected
OXA-23 whereas GES and PER in two cases. In one occasion, the mechanism responsible for
carbapenem resistance was not identified, since it was not among the tested PCRs. We may
argue that the inclusion of additional resistance genes in the molecular panel would improve
the clinical usefulness of this technique. However, the spreading of different resistance genes
underlines the limitation of molecular methods and the need to realize and use specific panels
of molecular tests according to local epidemiological data. Clinicians should be aware of the
most commonly mechanisms of resistance, related to local epidemiology and specific features
of each ward as well, before introducing any molecular method in their daily practice and eval-
uate its performance. Anyway, standard culture should be always performed together with
molecular tests, not only to identify those bacteria harbouring other resistance mechanisms,
but also to isolate the strain for subsequent analyses. We believe that additional studies should
be performed to assess validity of this technique especially as a supportive tool for decision
about timely antimicrobial strategy.
Conclusions
Xpert1 Carba-R may be considered an additional diagnostic tool for early detection of carba-
penem resistance among critically ill patients with abdominal sepsis. Local epidemiology
strongly influences the proportion of multidrug-resistant infected patients detectable by this
molecular method. Clinicians should be aware of local microbiological epidemiology before
introducing Xpert1 Carba-R in the diagnostic protocol of their ICUs. The inclusion of addi-
tional genes of carbapenem resistance in the panel of Xpert1 Carba-R may improve its diag-
nostic performance and clinical usefulness.
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